DSM, a global leader in biomedical materials science, today announced the use of its ComfortCoat hydrophilic coating on the delivery system of CID’s new Cre8 Drug Eluting Stent (DES), CE marked 16 July 2011.
CID chose ComfortCoat hydrophilic coating, a proprietary DSM product and technology, since it facilitates the treatment of more complex patient anatomies by enhancing the deliverability of its stent delivery systems during percutaneous coronary intervention procedures.
Recently-released data has not only proven the unmatched effectiveness of Cre8 DES in patients with coronary artery disease, but showcases the potential for this type of drug eluting stent system to help physicians shorten the dual antiplatelet therapy period for their patients. Furthermore, CID is leveraging the latest advanced delivery system technologies, particularly the ComfortCoat hydrophilic coating, in order to maximize acute device performances.
"The launch of Cre8 DES aligns with our mission of supporting interventional cardiologists and their patients with the development of innovative systems that positively impact patient outcomes, in terms of efficacy and safety, while also helping to reduce costs within the healthcare delivery system," said CID president and CEO Franco Vallana. "By collaborating with DSM, we are able to ensure interventional cardiologists receive the benefits of the world’s most advanced technologies within our drug eluting stent
systems."
"Our long-standing partnership with CID reaffirms our continued commitment to providing innovative material solutions for the cardiovascular market, which, ultimately, help to lower patient risk and improve procedural outcomes," said DSM Biomedical coatings business manager John Marugg. "As DSM’s materials portfolio continues to expand with novel coating materials, the successful launch of Cre8 DES is another strong testament to the value we provide medical device manufacturers across the globe."